Article

Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts.

Sunnybrook and Women's College Health Sciences Centre, Molecular and Cellular Biology Research, Toronto, Ontario M4N 3M5, Canada.
Cancer Research (Impact Factor: 8.65). 04/2002; 62(6):1838-46.
Source: PubMed

ABSTRACT Vascular endothelial growth factor (VEGF) occurs in at least five different isoforms because of alternative splicing of the gene. To investigate the roles of different VEGF isoforms in tumor blood vessel formation and tumorigenicity, the three major isoforms (VEGF(121), VEGF(165), and VEGF(189)) were overexpressed in an early-stage human melanoma cell line (WM1341B), which is VEGF-negative and nontumorigenic in immunodeficient mice. Although overexpression of VEGF(121) and VEGF(165) resulted in aggressive tumor growth, WM1341B cells transfected with VEGF(189) remained nontumorigenic and dormant on injection. Although tumor growth rate depended on the level and not the isoform of VEGF expressed, striking isoform-specific differences in vascular patterning were associated with VEGF(121)- versus VEGF(165)-dependent tumorigenic conversion of human melanoma. Thus, tumors overexpressing VEGF(165) generated dense, highly heterogeneous vessel networks that were distinctly different from those of tumors expressing VEGF(121) (poorly vascularized and necrotic). Paradoxically, although VEGF(165) expression appears to result in the most effective tumor perfusion, it is the expression of VEGF(121) that is observed during human malignant melanoma progression. Indeed, unbiased selection of spontaneously tumorigenic variants of WM1341B (by coinjection with Matrigel) led to predominant expression of the VEGF(121) isoform. The vascular patterning in these tumors (1341-P3N1, 1341-P3N2) resembled that of the VEGF(121)-transfected WM1341B tumors. These results suggest that, for reasons that remain to be elucidated, a "minimal" program of tumor vascularization may be favored during melanoma progression.

0 Bookmarks
 · 
44 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The growth and dissemination of tumors rely on an altered vascular network, which supports their survival and expansion and provides accessibility to the vasculature and a route of transport for metastasizing tumor cells. The remodeling of vascular structures through generation of new vessels (for example, via tumor angiogenesis) is a well studied, even if still quite poorly understood, process in human cancer. Antiangiogenic therapies have provided insight into the contribution of angiogenesis to the biology of human tumors, yet have also revealed the ease with which resistance to antiangiogenic drugs can develop, presumably involving alterations to vascular signaling mechanisms. Furthermore, cellular and/or molecular changes to pre-existing vessels could represent subtle pre-metastatic alterations to the vasculature, which are important for cancer progression. These changes, and associated molecular markers, may forecast the behavior of individual tumors and contribute to the early detection, diagnosis and prognosis of cancer. This review, which primarily focuses on the blood vasculature, explores current knowledge of how tumor vessels can be remodeled, and the cellular and molecular events responsible for this process.Oncogene advance online publication, 5 August 2013; doi:10.1038/onc.2013.304.
    Oncogene 08/2013; · 8.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anti-angiogenic therapy based on blocking the actions of vascular endothelial growth factor-A (VEGF) can lead to 'normalization' of blood vessels in both animal and human tumors. Differential expression of VEGF isoforms affects tumor vascular maturity, which could influence the normalization process and response to subsequent treatment. Fibrosarcoma cells expressing only VEGF120 or VEGF188 isoforms were implanted either subcutaneously (s.c.) or in dorsal skin-fold 'window' chambers in SCID mice. VEGF120 was associated with vascular fragility and hemorrhage. Tumor-bearing mice were treated with repeat doses of SU5416, an indolinone receptor tyrosine kinase (RTK) inhibitor with activity against VEGFR-2 and proven pre-clinical ability to induce tumor vascular normalization. SU5416 reduced vascularization in s.c. implants of both VEGF120 and VEGF188 tumors. However, in the window chamber, SU5416 treatment increased red cell velocity in VEGF120 (representing vascular normalization) but not VEGF188 tumors. SU5416 treatment had no effect on growth or necrosis levels in either tumor type but tended to counteract the increase in interstitial fluid pressure (IFP) seen with growth of VEGF120 tumors. SU5416 pre-treatment resulted in the normally fragile blood vessels in VEGF120-expressing tumors becoming resistant to the vascular damaging effects of the tubulin-binding vascular disrupting agent (VDA), combretastatin A4 3-O-phosphate (CA4P). Thus, vascular normalization induced by anti-angiogenic treatment can reduce the efficacy of subsequent VDA treatment. Expression of VEGF120 made tumors particularly susceptible to vascular normalization by SU5416, which in turn made them resistant to CA4P. Therefore VEGF isoform expression may be useful for predicting response to both anti-angiogenic and vascular-disrupting therapy. © 2013 Wiley Periodicals, Inc.
    International Journal of Cancer 05/2013; · 6.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis, defined as new vessel growth from a pre-existing vessel, has been shown to be crucial for tumor survival and growth in several lineage-unrelated malignancies including melanoma. The concept of vasculogenic mimicry, a highly patterned microcirculation independent of angiogenesis, has also been described in melanoma. The prognostic value of vascular invasion, characterized by the presence of tumor cells within vascular channels, in melanoma remains controversial as in the current American Joint Committee on Cancer-staging system for melanoma vascular invasion is not included for microscopic staging purposes. This review summarizes contemporary understanding of these three processes i.e. angiogenesis, vasculogenic mimicry, and vascular invasion in an effort to uncover putative targets as therapeutic strategies in melanoma.
    Expert Review of Anti-infective Therapy 02/2014; · 2.07 Impact Factor

Full-text (2 Sources)

View
10 Downloads
Available from
Jun 2, 2014